Medicina de precisió: polítiques, promeses i preus

• Autores: Salvador Peiró Moreno
• Localización: Revista econòmica de Catalunya, ISSN 1135-819X, Nº. 81, 2020 (Ejemplar dedicado a: Salut i sistema sanitari), págs. 79-85
• Idioma: catalán
• Enlaces
  • Texto completo
• Referencias bibliográficas
  • Cole, A.L.; Dusetzina, S.B. (2018). “Generic Price Competition For Specialty Drugs: Too Little, Too Late?”. Health Affairs 37(5):738-42.
  • Davis, C.; Naci, H.; Gurpinar, E.; Poplavska, E.; Pinto, A.; Aggarwal, A. (2017). “Availability of evidence of benefits on overall survival...
  • Ferrario, A.; Kanavos, P. (2015). “Dealing with uncertainty and high prices of new medicines: a comparative analysis of the use of managed...
  • Hollands, G.J.; French, D.P.; Griffin, S.J.; Prevost, A.T.; Sutton, S.; King, S., et al. (2016). “The impact of communicating genetic risks...
  • Janssens, A.C.J.W; Joyner, M.J. (2019). “Polygenic Risk Scores That Predict Common Diseases Using Millions of Single Nucleotide Polymorphisms:...
  • Jayasundara, K.; Hollis, A.; Krahn, M.; Mamdani, M.; Hoch, J.S.; Grootendorst, P. (2019). “Estimating the clinical cost of drug develop ment...
  • Joyner, M.J; Paneth, N. (2019). “Promises, promises, and precision medicine”. Journal of Clinical Investigation 129(3):946-8.
  • Marquart, J.; Chen, E.Y.; Prasad, V. (2018). “Estimation of the Percentage of US Patients With Cancer Who Benefit From Genome Driven Oncology”....
  • Martinalbo, J.; Bowen, D.; Camarero, J.; Chapelin, M.; Démolis, P.; Foggi, P.; et al (2016). “Early market access of cancer drugs in the...
  • Messori, A.; Cicchetti, A.; Patregani, L. (2010). “Orphan drugs. Relating price determination to disease prevalence”. British Medical Journal...
  • Onakpoya, I.J.; Spencer, E.A.; Thompson, M.J.; Heneghan, C.J. (2015). “Effectiveness, safety and costs of orphan drugs: an evidence based...
  • Oyagüez, I.; Frías, C.; Seguí, M.A.; Gómez-Barrera, M.; Casado, M.A.; Queralt Gorgas, M. (2013). “Efficiency of oncologic treatments for...
  • Peiró, S. (2015). “La incorporación de nuevos medicamentos al SNS: innovación, accesibilidad y sostenibilidad”. Gestión Clínica y Sanitaria...
  • Peiró, S. (2019). “¿Por qué son tan caros los medicamentos?”. II Congreso EconSaludSur. Evaluación económica en salud. Rectorado de la Universidad...
  • Peiró, S.; del Llano, J. (2019). “La perspectiva de la política y la gestión sanitaria ante la medicina de precisión”. Gestión Clínica y...
  • Phillips, M.I. (2013). “Big Pharma’s new model in orphan drug and rare diseases”. Expert Opinion Orphan Drugs 1(1):1-3.
  • Picavet, E.; Cassiman, D.; Simoens, S. (2013). “Do ultra-orphan medicinal products warrant ultra-high prices? a review”. Orphan Drugs Research...
  • Ramsey, S.D. (2015). “How state and federal policies as well as advances in genome science contribute to the high cost of cancer drugs”....
  • Rey-Lopez, J.P.; Lumbreras, B.; Ponce-Lorenzo, J.J.; Campillo-Artero, C.; Pastor-Valero, M. (2019). “Precision medicine: Will technology be...
  • Roos, J.C.; Hyry, H.I.; Cox, T.M. (2010). “Orphan drug pricing may warrant a competition law investigation”. British Medical Journal 341:c6471.
  • Sacristán, J.A.; Oliva, J.; Campillo-Artero, C.; Puig-Junoy, J.; Pinto-Prades, J.L.; Dilla, T.; et al. (2019). “¿Qué es una intervención sanitaria...
  • Young, K.E.; Soussi, I.; Toumi, M. (2017). “The perverse impact of external reference pricing (ERP): a comparison of orphan drugs affordability...